{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:20:09Z","timestamp":1791566409563,"version":"4.3.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to analyze the clinical characteristics of immune-related myocarditis caused by cadonilimab, thereby providing a reference for its safe clinical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on the medical records of 12 patients diagnosed with immune-related myocarditis caused by cadonilimab at our hospital between January 1st, 2021 and December 31, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The incidence of immune-related myocarditis caused by cadonilimab was 2.45% (95%CI:1.30%-4.20%). Among the 12 patients who developed immune-related myocarditis, the majority were female (66.7%) and aged 65 years or younger (83.33%). The median time to onset was 49 days(IQR 27.75, 78), with 10 cases occurring within 90 days following the initial administration. 7 patients were off-label use. Additionally, 7 patients were accompanied by other immune checkpoint inhibitor (ICI)-related adverse events (irAEs), such as hypothyroidism, hepatitis and infusion reactions. 9 patients received glucocorticoid treatment and all of the 12 patients showed improvement and recovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The clinical use of cadonilimab is complex, necessitating individualized monitoring for immune-related myocarditis based on the patient\u2019s condition. Furthermore, patient education is essential to ensure medication safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1671973","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T04:12:36Z","timestamp":1760674356000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of the twelve cases of immune-related myocarditis caused by cadonilimab"],"prefix":"10.3389","volume":"15","author":[{"given":"Po","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107355","article-title":"A multicenter, open-label phase Ib\/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104\u2013202 study)","volume":"184","author":"Zhao","year":"2023","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03450-4","article-title":"First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial","volume":"31","author":"Shen","year":"2025","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet\u00a0Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01761-9","article-title":"Cadonilimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"B5","article-title":"Recommendations for clinical diagnosis and treatment of immune checkpoint inhibitors-associated myocarditis","volume":"30","author":"Wang","year":"2023","journal-title":"Chin J Clin Med"},{"key":"B6","unstructured":"Guidelines for the Collection and Reporting the Individual Adverse drug Reactions (No. 131 of 2018)\n          \n          \n          \n          2018"},{"key":"B7","volume-title":"Chinese Society of Clinical Oncology (CSCO) Guidelines on toxicity management related to immune checkpoint inhibitors","year":"2023"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jop.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Oncol Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet (London England)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02519-0","article-title":"A phase Ib\/II study of cadonilimab (PD-1\/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer","volume":"130","author":"Chen","year":"2024","journal-title":"Br J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.03.099","article-title":"An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)","author":"Tang","year":"2025","journal-title":"Proc Soc Gynecologic Oncol F"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00977-w","article-title":"Treatment advances across the cervical cancer spectrum","volume":"22","author":"Francoeur","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-025-01698-y","article-title":"The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis","volume":"18","author":"Chen","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B14","first-page":"6","volume-title":"Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of ovarian Cancer","year":"2023"},{"key":"B15","article-title":"One case of immune-mediated myocarditis induced by Cadonilimab monoclonal antibody","volume":"40","author":"Ding","year":"2024","journal-title":"J Clin Cardiology (China)"},{"key":"B16","article-title":"A case of immune-related myocarditis caused by cadonilimab in treatment of advanced gastric cancer","volume":"33","author":"Zhang","year":"2024","journal-title":"Chin J New Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/s0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet (London England)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"17324","DOI":"10.1038\/s41598-021-96467-5","article-title":"Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data","volume":"11","author":"Makunts","year":"2021","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"New Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002553","article-title":"Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis","volume":"9","author":"Puzanov","year":"2021","journal-title":"J immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1101\/2024.06.02.24308336","article-title":"Predictors and risk score for immune checkpoint-inhibitor-associated myocarditis severity","author":"Power","year":"2024","journal-title":"medRxiv: preprint server Health Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.100","article-title":"Advances in research on molecular markers in immune checkpoint inhibitor-associated myocarditis","volume":"2","author":"Shao","year":"2023","journal-title":"Cancer Innovation"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-023-03481-8","article-title":"The role of circulating biomarkers in predicting the 30-day mortality of immune checkpoint inhibitors-related myocarditis: a retrospective cohort study","volume":"19","author":"Zhuang","year":"2024","journal-title":"Internal Emergency Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-24-556","article-title":"Development of peripheral biomarker-based prognostic nomograms for short-term and long-term survival in immune checkpoint inhibitor-associated myocarditis","volume":"15","author":"Guan","year":"2025","journal-title":"Cardiovasc diagnosis Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.124.038719","article-title":"Predictors of long-term survival in patients with immune checkpoint inhibitor-associated myocarditis","volume":"14","author":"Dubey","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"B28","article-title":"Real-world cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a retrospective controlled cohort study","volume":"11","author":"Zhang","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2512645","article-title":"A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers","volume":"21","author":"Xu","year":"2025","journal-title":"Hum Vaccines immunotherapeutics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-023-01400-4","article-title":"Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer","volume":"41","author":"Xu","year":"2023","journal-title":"Investigational New Drugs"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7460","article-title":"Early identification of severe immune checkpoint inhibitor associated myocarditis: From an electrocardiographic perspective","volume":"13","author":"Gao","year":"2024","journal-title":"Cancer Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101478","article-title":"Electrocardiographic features of immune checkpoint inhibitor-associated myocarditis","volume":"48","author":"Song","year":"2023","journal-title":"Curr problems Cardiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/fjc.0000000000001456","article-title":"Treatment of immune checkpoint inhibitor-associated myocarditis","volume":"83","author":"Heemelaar","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1455347","article-title":"Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review","volume":"16","author":"Man","year":"2025","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1404045","article-title":"Case report: Regression after low-dose glucocorticoid therapy in a case of acute immune myocarditis induced by anti-PD-1 therapy for NSCLC","volume":"14","author":"Chen","year":"2024","journal-title":"Front Oncol"}],"updated-by":[{"DOI":"10.3389\/fonc.2025.1730005","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1671973\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T08:44:29Z","timestamp":1764146669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1671973\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":37,"alternative-id":["10.3389\/fonc.2025.1671973"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1671973","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"article-number":"1671973"}}